Faster global financial news!
RedHill Biopharma (RDHL) acquires commercialization rights for Rebyota and Clenpiq for $12 million upfront, with the two products' combined sales reaching $37.5 million in 2025.
The transaction involves the global exclusive commercialization rights for Rebyota and the US exclusive commercialization rights for Clenpiq, sold by Ferring Pharmaceuticals. The agreement has an initial term of 13 years and includes tiered sales royalties ranging from 5% to 20%, along with other contingent payments.
No AI analysis yet. Tap the "AI Analysis" button above to generate one now.
Disclaimer: This content reflects the author's personal views only and does not constitute investment advice.
Previous: Analysis: CoreWeave (CRWV) stock has been on a downtrend since April, falling nearly 5% on Wednesday, with analysts suggesting it's suitable for put option strategies.
|
Next: SolarEdge shares fell 4% on analyst day, despite the release of an 800 VDC power framework in collaboration with NVIDIA; investors focused more on revenue timing than lab results.
24H Trending
-
1
The bank raised its 2027 humanoid robot sales forecast for Unitree Robotics to 31,701 units
-
2
Meta's earnings triggered a significant widening of AI credit spreads, with its Credit Default Swaps (CDS) reaching an all-time high
-
3
shows that the computational power consumption for training humanoid robot full-body motion controllers can be compressed by over 1000 times
-
4
Cryptocurrency Basics: Definition, Development, and Secure Investment Strategies
-
5
Toncoin Institutional Investor Analysis: Funding, Custody, and Market Impact of the Telegram Ecosystem
-
6
Ethereum Monetary Theory: From EIP-1559 to the "Ultra Sound Money" Vision
-
7
Hong Kong aims to increase its total gold storage capacity by more than tenfold to 2,000 tons by 2030
-
8
Israel will hold general elections on Tuesday, with war, security, the economy, and coalition formation being the main issues
-
9
AI, a Chinese provider of high-quality AI token production services, recently completed a Series B funding round exceeding RMB 1.3 billion
-
10
Boosted by this news, SK Hynix's stock price rose over 2% at one point on Monday
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
